Ingevity Corp (NGVT)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NYSE
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ingevity Corp (NGVT) Stock Forecast
Analysts expect Ingevity (NGVT) to earn $5.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.11B. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 10.6% and revenue estimates rise 0.9%.
- Fiscal year ending Dec 31, 2026
- $5.39
- EPS consensus, revenue $1.11B
- Fiscal year ending Dec 31, 2027
- $5.96
- EPS consensus, revenue $1.12B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.39 | $5.30 to $5.48 | 3 | $1.11B | $1.10B to $1.11B | 3 |
| Dec 31, 2027 | $5.96 | $5.80 to $6.19 | 3 | $1.12B | $1.10B to $1.14B | 3 |
Quarterly Estimates
The EPS consensus rises from $0.89 for the quarter ending Dec 31, 2026 to $1.21 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.89 | $0.76 to $1.01 | 5 | $236.54M | $221.48M to $249.69M | 4 |
| Mar 31, 2027 | $1.21 | $1.13 to $1.28 | 2 | $252.35M | $250.00M to $254.70M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.9% from $5.24.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.39 | $5.24 | $5.24 | $5.24 | $5.24 | +2.9% |
| Fiscal year ending Dec 31, 2027 | $5.96 | $6.01 | $6.01 | $6.01 | $6.01 | -0.8% |
| Quarter ending Mar 31, 2027 | $1.21 | $1.19 | $1.19 | $1.19 | $1.19 | +1.7% |
Frequently Asked Questions About NGVT
What is the NGVT stock forecast?
Consensus analyst estimates put Ingevity's EPS at $5.39 for the fiscal year ending Dec 31, 2026, on revenue of $1.11B. The consensus rating from 3 analysts is Buy.
How do analysts rate NGVT stock?
Of 3 analysts covering Ingevity, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NGVT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.39, with estimates from $5.30 to $5.48 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.96, with estimates from $5.80 to $6.19 from 3 analysts.
What revenue do analysts expect from Ingevity next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.11B, with estimates from $1.10B to $1.11B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.12B, with estimates from $1.10B to $1.14B.
How many analysts cover NGVT?
3 analysts rate Ingevity stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NGVT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors